MedTrace Logo

Alvopem® (Pemetrexed) Safety Assessment

NCT04843007 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2024-10-23

Study results available
· View outcomes & findings →

Summary

The present study was a phase IV, post-marketing, observational study for safety evaluation of Alvopem® use in Iranian patients with non-small cell lung cancer and malignant pleural mesothelioma. No control groups were included in the study design.

The primary objective of this study was safety assessment, including the incidence of adverse events (AEs).

Conditions

  • Non Small Cell Lung Cancer
  • Malignant Pleural Mesothelioma

Interventions

DRUG

Pemetrexed

Alvopem® was administered every 3 weeks with a dose of 500 mg/m\^2

Sponsors & Collaborators

  • NanoAlvand

    lead INDUSTRY

Principal Investigators

  • Adnan Khosravi, Assoc. Prof. · National Research Institute of Tuberculosis and Lung Disease (NRITLD)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-15
Primary Completion
2020-01-22
Completion
2020-01-22

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04843007 on ClinicalTrials.gov